Company

Medigen Vaccine Biologics Corp

Headquarters: Taipei, Taiwan

TWSE: 6547 -3.24%

Market Cap

TW$17.45 Billion

TWD as of July 1, 2024

US$535.9 Million

Market Cap History

Medigen Vaccine Biologics Corp market capitalization over time

Evolution of Medigen Vaccine Biologics Corp market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Medigen Vaccine Biologics Corp

Detailed Description

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Medigen Vaccine Biologics Corp has the following listings and related stock indices.


Stock: TWSE: 6547 wb_incandescent

Details

Headquarters:

No. 16, Neihu Road

7th Floor Lane 120 Sec. 1

Taipei, 114

Taiwan

Phone: 886 2 7745 0830

Fax: 886 2 2658 8980